Database : MEDLINE
Search on : adrenocortical and hyperfunction [Words]
References found : 2138 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 214 go to page                         

  1 / 2138 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29208661
[Au] Autor:Eisenhofer G; Masjkur J; Peitzsch M; Di Dalmazi G; Bidlingmaier M; Grüber M; Fazel J; Osswald A; Beuschlein F; Reincke M
[Ad] Address:Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Grame.Eisenhofer@uniklinikum-dresden.de.
[Ti] Title:Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping Patients with Cushing Syndrome.
[So] Source:Clin Chem;64(3):586-596, 2018 Mar.
[Is] ISSN:1530-8561
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Diagnosis of Cushing syndrome requires a multistep process that includes verification of hypercortisolism followed by identification of the cause of adrenocortical hyperfunction. This study assessed whether pituitary, ectopic, and adrenal subtypes of Cushing syndrome were characterized by distinct plasma steroid profiles that might assist diagnosis. METHODS: In this retrospective cross-sectional study, mass spectrometric measurements of a panel of 15 plasma steroids were applied to 222 patient samples tested for Cushing syndrome. Disease was excluded in 138 and confirmed in 51 patients with pituitary Cushing syndrome, 12 with ectopic adrenocorticotropin secretion, and 21 with adrenal disease. Another 277 age- and sex-matched hypertensive and normotensive volunteers were included for comparison. RESULTS: Compared with patients without disease, the largest increases in plasma steroids among patients with Cushing syndrome were observed for 11-deoxycortisol (289%), 21-deoxycortisol (150%), 11-deoxycorticosterone (133%), corticosterone (124%), and cortisol (122%). Patients with ectopic disease showed the most prominent increases, but there was considerable variation for other steroids according to subtype. Patients with adrenal disease had the lowest concentrations of androgens, whereas those with ectopic and pituitary disease showed the lowest concentrations of aldosterone. Plasma 18-oxocortisol was particularly low in ectopic disease. With the use of 10 selected steroids, subjects with and without different Cushing syndrome subtypes could be discriminated nearly as closely as with the use of salivary and urinary free cortisol, dexamethasone-suppressed cortisol, and plasma adrenocorticotropin (9.5% vs 5.8% misclassification). CONCLUSIONS: Patients with different subtypes of Cushing syndrome show distinctive plasma steroid profiles that may offer a supplementary single-test alternative for screening purposes.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:In-Data-Review
[do] DOI:10.1373/clinchem.2017.282582

  2 / 2138 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29244921
[Au] Autor:Trush VV; Sobolev VI
[Ti] Title:Influence of iatrogenic hypercorticoidism induced by long-term application of dexamethasone on power of muscular contraction of white rats.
[So] Source:Patol Fiziol Eksp Ter;60(4):39-46, 2016 Oct-Dec.
[Is] ISSN:0031-2991
[Cp] Country of publication:Russia (Federation)
[La] Language:eng
[Ab] Abstract:Research objective consisted in detection of nature of the changes of the myothermiс and the ergometric parameters of the contraction of the forward tibial muscle of rats in the course of performing of the tiring work at the saturation of an organism by therapeutic doses of dexamethasone. Method: The experiments were performed on sexually mature rats-females (200-220 g), divided into control (n = 10) and experimental (n = 60) groups. The animals of experimental group received dexamethasone (D, KRKA, Slovenia) in a dose of 0,25 mg/kg (intraperitoneal, 1 time in 2 days) during from 10 to 60 days. On anesthetized animals (sodium thiopental, 100 mg/kg) with the use of myothermia and ergographia the nature of change of power of the muscle's contraction in the course of the performance of the tiring work (3 six-second tetanus with external loading of 80 g) was studied. Restults: At the initial stage of the development of iatrogenic hypercorticoidism (after 5-20 injections of D) the initial value of the external work of the muscle in comparison with the control is significantly lower (for 30-52%) and the temperature cost of the unit of the work (TCMW), on the contrary, - is higher (for 26-82%). On the end of the 2-month period of application of D the initial values of the power parameters of the muscle came back to control level. During the performance of the tiring tetanus in animal experimental groups the decline of the external work of the muscle is greater (69-73%) compared with the control (55%). This effect does not depend of the number of injections of D, which indicates about a high pathophysiological activity of glucocorticoid concerning working capacity of the muscle. At expressed fatigue the TCMW always increases from 104% (5 injections of D) to 230% (20 injections); at control animals the effect of the tiring work on TCMW is significantly weaker (28%). At long-term application of D (2 months) the described effect of the preparation is weakened, though remains accurately expressed. Conclusion: The obtained data are considered from the point of view of formation at the hypercorticoidizm of the pathophysiological mechanism - the increase of power cost of muscular work. The revealed effect of D can be the cornerstone of the formation of the number of the pathophysiological mechanisms in neuromuscular system including causing the development of the myopathy at the hypercorticoidizm.
[Mh] MeSH terms primary: Adrenocortical Hyperfunction
Dexamethasone/adverse effects
Muscle Contraction
Muscle Strength
[Mh] MeSH terms secundary: Adrenocortical Hyperfunction/chemically induced
Adrenocortical Hyperfunction/physiopathology
Animals
Dexamethasone/pharmacology
Male
Rats
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:7S5I7G3JQL (Dexamethasone)
[Em] Entry month:1801
[Cu] Class update date: 180118
[Lr] Last revision date:180118
[Js] Journal subset:IM
[Da] Date of entry for processing:171216
[St] Status:MEDLINE

  3 / 2138 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28932767
[Au] Autor:Haan RR; Visser JBR; Pons E; Feelders RA; Kaymak U; Hunink MGM; Visser JJ
[Ad] Address:Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands.
[Ti] Title:Patient-specific workup of adrenal incidentalomas.
[So] Source:Eur J Radiol Open;4:108-114, 2017.
[Is] ISSN:2352-0477
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:PURPOSE: : To develop a clinical prediction model to predict a clinically relevant adrenal disorder for patients with adrenal incidentaloma. MATERIALS AND METHODS: : This retrospective study is approved by the institutional review board, with waiver of informed consent. Natural language processing is used for filtering of adrenal incidentaloma cases in all thoracic and abdominal CT reports from 2010 till 2012. A total of 635 patients are identified. Stepwise logistic regression is used to construct the prediction model. The model predicts if a patient is at risk for malignancy or hormonal hyperfunction of the adrenal gland at the moment of initial presentation, thus generates a predicted probability for every individual patient. The prediction model is evaluated on its usefulness in clinical practice using decision curve analysis (DCA) based on different threshold probabilities. For patients whose predicted probability is lower than the predetermined threshold probability, further workup could be omitted. RESULTS: : A prediction model is successfully developed, with an area under the curve (AUC) of 0.78. Results of the DCA indicate that up to 11% of patients with an adrenal incidentaloma can be avoided from unnecessary workup, with a sensitivity of 100% and specificity of 11%. CONCLUSION: : A prediction model can accurately predict if an adrenal incidentaloma patient is at risk for malignancy or hormonal hyperfunction of the adrenal gland based on initial imaging features and patient demographics. However, with most adrenal incidentalomas labeled as nonfunctional adrenocortical adenomas requiring no further treatment, it is likely that more patients could be omitting from unnecessary diagnostics.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1709
[Cu] Class update date: 170924
[Lr] Last revision date:170924
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.1016/j.ejro.2017.08.002

  4 / 2138 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28838299
[Au] Autor:Boland LA; Barrs VR
[Ad] Address:Valentine Charlton Cat Centre, Sydney School of Veterinary Science, Faculty of Science, University of Sydney, NSW, Australia.
[Ti] Title:Peculiarities of feline hyperadrenocorticism: Update on diagnosis and treatment.
[So] Source:J Feline Med Surg;19(9):933-947, 2017 Sep.
[Is] ISSN:1532-2750
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Practical relevance: Hyperadrenocorticism (HAC) is a relatively uncommon endocrinopathy of older cats, with a mean age at diagnosis of 10 years. In addition to pituitary-dependent and adrenal-dependent hypercortisolism, clinical signs of HAC can result from adrenal sex steroid-producing tumours. Clinical challenges: While HAC in cats has many similarities to canine HAC, there are key differences in presentation, diagnosis and response to therapy. Most, but not all, cats with HAC have concurrent diabetes mellitus, which is often insulin resistant. Up to a third of cats with HAC have extreme skin fragility and are at high risk of debilitating iatrogenic skin tears during diagnostic or therapeutic interventions. Infections of the skin and nail beds, and urinary, respiratory and gastrointestinal tract, secondary to cortisol-induced immune suppression, are also common. Cats respond differently to dogs to adrenal function tests including adrenocorticotropic hormone (ACTH) stimulation and dexamethasone suppression tests; a 10-fold higher dose of dexamethasone is recommended in cats to screen for HAC. Curative treatment options include adrenalectomy or transsphenoidal hypophysectomy. Radiation or medical treatment may improve clinical signs. The response to mitotane therapy is poor. While trilostane is the medical treatment of choice based on retrospective studies, investigations into the pharmacokinetics of this drug in cats are lacking. Global importance: Feline HAC occurs worldwide and is not associated with any purebreed predisposition. Although uncommon, adrenal sex steroid-producing tumours have a higher prevalence in cats than in dogs. Evidence base: The information in this review is drawn from over 180 reported cases of feline HAC. Reports investigating clinical presentation, clinicopathological findings and treatment outcomes are observational, retrospective multiple case series (EBM grade III) or single case reports (EBM grade IV). While most endocrine testing studies for diagnosis are cohort controlled analytical studies (EBM grade III), prospective, randomised, placebo-controlled studies have been performed (EBM grade I).
[Mh] MeSH terms primary: Adrenocortical Hyperfunction/veterinary
Cat Diseases/diagnosis
Cat Diseases/therapy
[Mh] MeSH terms secundary: Adrenocortical Hyperfunction/diagnosis
Adrenocortical Hyperfunction/therapy
Animals
Cats
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171010
[Lr] Last revision date:171010
[Js] Journal subset:IM
[Da] Date of entry for processing:170826
[St] Status:MEDLINE
[do] DOI:10.1177/1098612X17723245

  5 / 2138 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28407319
[Au] Autor:Johnson CM; Kass PH; Cohen TA; Feldman EC
[Ad] Address:Department of Small Animal Internal Medicine, Animal Specialty and Emergency Center, Los Angeles, CA.
[Ti] Title:Effect of Intravenous or Perivascular Injection of Synthetic Adrenocorticotropic Hormone on Stimulation Test Results in Dogs.
[So] Source:J Vet Intern Med;31(3):730-733, 2017 May.
[Is] ISSN:1939-1676
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Standard protocols for adrenocorticotropic hormone (ACTH) stimulation testing (ACTHst) often involve intravenous (IV) injection of corticotropin. ACTH might be unintentionally injected into the perivascular (PV) space. OBJECTIVE: To compare stimulation test results after IV and PV injections of ACTH. ANIMALS: Twenty privately owned dogs were studied: 10 healthy and 10 with trilostane-treated naturally occurring hyperadrenocorticism (HAC). METHODS: Prospective study. Each of 20 dogs underwent 2 ACTHst not <4 nor more than 14 days apart. Five healthy and 5 HAC dogs had an IV ACTHst first and PV second; 5 healthy and 5 HAC dogs had a PV ACTHst first and IV second. Blood samples for measurement of serum cortisol concentration were collected before and 1 hour after ACTH administration. RESULTS: No significant difference in results was demonstrated when comparing serum cortisol concentrations after IV and PV ACTH administration in all 20 dogs (median µg/dL; interval µg/dL: 8.2; 1.4-17.4 versus 7.8; 0.9-16.9; P = .23). No significant difference in results was demonstrated when comparing serum cortisol concentrations after IV and PV ACTH administration in the 10 healthy dogs (median µg/dL; interval µg/dL: 10.9; 7.3-17.4 versus 10.6; 7.1-16.9; P = .54) or in the 10 HAC dogs (median µg/dL; interval µg/dL: 6.3; 1.4-8.6 versus 5.2; 0.9-8.7; P = .061). CONCLUSIONS AND CLINICAL IMPORTANCE: Perivascular administration of ACTH does not significantly alter stimulation test results in healthy dogs or in dogs with HAC undergoing therapy with trilostane.
[Mh] MeSH terms primary: Adrenocortical Hyperfunction/veterinary
Adrenocorticotropic Hormone/administration & dosage
Dog Diseases/diagnosis
Hydrocortisone/blood
[Mh] MeSH terms secundary: Adrenocortical Hyperfunction/diagnosis
Animals
Case-Control Studies
Dog Diseases/blood
Dogs
Female
Injections, Intravenous/veterinary
Injections, Subcutaneous/veterinary
Male
[Pt] Publication type:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Name of substance:9002-60-2 (Adrenocorticotropic Hormone); WI4X0X7BPJ (Hydrocortisone)
[Em] Entry month:1710
[Cu] Class update date: 171023
[Lr] Last revision date:171023
[Js] Journal subset:IM
[Da] Date of entry for processing:170414
[St] Status:MEDLINE
[do] DOI:10.1111/jvim.14708

  6 / 2138 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28391254
[Au] Autor:Katanic D; Kafka D; Zivojinov M; Vlaski J; Budakov Z; Knezevic Pogancev M; Vorgucin I; Cuk T
[Ad] Address:Paediatrician-Endocrinologist, Faculty of Medicine, University Paediatric Clinic, Novi Sad.
[Ti] Title:Primary pigmented nodular adrenocortical disease: literature review and case report of a 6-year-old boy.
[So] Source:J Pediatr Endocrinol Metab;30(5):603-609, 2017 May 01.
[Is] ISSN:2191-0251
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:Cushing's syndrome is rare in childhood and is usually caused by a pituitary adenoma. Primary hyperfunction of adrenal glands is less frequent, particularly primary pigmented nodular adrenocortical disease (PPNAD). It occurs usually in children and adolescents, with female preponderance, while Cushing's disease has increased frequency in prepubertal males. A case of a 6-year-old boy is presented with isolated non-familiar PPNAD. The clinical pattern involved Cushingoid appearance, hypertension, virilization and depressive mood. Laboratory analyses showed loss of circadian rhythm of cortisol, undetectable adrenocorticotropic hormone (ACTH) level, impaired fasting glucose, polycythemia and elevated white blood count (WBC). Radiology investigation revealed a slightly enlarged medial branch of the left adrenal gland and a normal right one, so a unilateral adrenalectomy was performed. Pathohistology described multiple dark brownish pigmented nodules of various sizes confined to the cortex. Contralateral adrenalectomy was done 3 months later. Follow-up of 3 years was uneventful, except for one adrenal crisis during an intercurrent respiratory illness.
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1704
[Cu] Class update date: 170608
[Lr] Last revision date:170608
[St] Status:In-Process

  7 / 2138 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28266313
[Au] Autor:Wong CJ; Koch M; Behling-Kelly EL
[Ad] Address:Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, 602 Tower Rd, Ithaca, NY 14853, United States. Electronic address: cjw228@cornell.edu.
[Ti] Title:Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs.
[So] Source:Res Vet Sci;111:1-8, 2017 Apr.
[Is] ISSN:1532-2661
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Thrombosis is a serious complication of many canine diseases and may be related to decreased fibrinolytic potential. Plasminogen activator inhibitor-1 (PAI-1) is the key regulator of fibrinolysis with increased levels demonstrated in states of pro-thrombosis and abnormal lipid metabolism. Our objective was to develop and validate a canine PAI-1 activity assay and test whether dogs with hyperadrenocorticism or diabetes mellitus that are hyperlipidemic/dyslipidemic have increased plasma PAI-1 activity. Functionally active PAI-1 in the plasma sample was incubated with recombinant tissue plasminogen activator (tPA), allowing the formation of a 1:1 stoichiometric inactive complex. Residual unbound tPA was then reacted with excess plasminogen in the presence of a colorimetric plasmin substrate. Plasmin production is quantified by computing the area under the curve of time (x) vs optical density (y) plot and converted to tPA IU/mL by comparison to a calibration curve of tPA standards. PAI-1 activity was determined by calculating the proportion of exogeneous tPA suppressed by PAI-1 in plasma. Assay verification included assessment of linearity, specificity, precision, sensitivity, and stability. PAI-1 activity was increased in hyperlipidemic compared to healthy dogs, but there was no significant difference between dogs with hyperadrenocorticism and diabetes mellitus. A near significant decrease in activity was detected in thawed plasma stored for 20h at 4°C. Our successfully validated assay offers a new tool for investigating fibrinolysis in dogs. Investigation of PAI-1 activity in dogs with other diseases associated with an increased risk of thrombosis would be valuable. Future studies of PAI-1 activity should consider its lability.
[Mh] MeSH terms primary: Adrenocortical Hyperfunction/blood
Diabetes Mellitus/blood
Dog Diseases/metabolism
Hyperlipidemias/veterinary
Plasminogen Activator Inhibitor 1/metabolism
[Mh] MeSH terms secundary: Adrenocortical Hyperfunction/complications
Adrenocortical Hyperfunction/metabolism
Animals
Diabetes Mellitus/metabolism
Dog Diseases/blood
Dogs
Female
Humans
Hyperlipidemias/blood
Hyperlipidemias/complications
Male
Plasminogen Activator Inhibitor 1/blood
Plasminogen Activator Inhibitor 1/genetics
Sensitivity and Specificity
Serologic Tests
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Plasminogen Activator Inhibitor 1)
[Em] Entry month:1707
[Cu] Class update date: 170705
[Lr] Last revision date:170705
[Js] Journal subset:IM
[Da] Date of entry for processing:170308
[St] Status:MEDLINE

  8 / 2138 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28222025
[Au] Autor:Farrugia FA; Martikos G; Surgeon C; Tzanetis P; Misiakos E; Zavras N; Charalampopoulos A
[Ti] Title:Radiology of the adrenal incidentalomas. Review of the literature.
[So] Source:Endocr Regul;51(1):35-51, 2017 Jan 01.
[Is] ISSN:1210-0668
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:The term "adrenal incidentaloma" is a radiological term. Adrenal incidentalomas are adrenal tumors discovered in an imaging study that has been obtained for indications exclusive to adrenal conditions (Udelsman 2001; Linos 2003; Bulow et al. 2006; Anagnostis et al. 2009). This definition excludes patients undergoing imaging testing as part of staging and work-up for cancer (Grumbach et al. 2003; Anagnostis et al. 2009). Papierska et al. (2013) have added the prerequisite that the size of a tumor must be "greater than 1cm in diameter", in order to be called incidentaloma. Although in the most cases these masses are non-hypersecreting and benign, they still represent an important clinical concern because of the risk of malignancy or hormone hyperfunction (Barzon et al. 2003). Th e adrenal tumors belong to the commonest incidental findings having been discovered (Kanagarajah et al. 2012).
[Mh] MeSH terms primary: Adrenal Cortex Neoplasms/diagnostic imaging
Adrenal Gland Neoplasms/diagnostic imaging
Adrenocortical Adenoma/diagnostic imaging
Adrenocortical Carcinoma/diagnostic imaging
Pheochromocytoma/diagnostic imaging
[Mh] MeSH terms secundary: 3-Iodobenzylguanidine
Addison Disease/diagnostic imaging
Adrenal Gland Diseases/diagnostic imaging
Cushing Syndrome/diagnostic imaging
Diffusion Magnetic Resonance Imaging
Fluorodeoxyglucose F18
Hemorrhage/diagnostic imaging
Humans
Hyperaldosteronism/diagnostic imaging
Indium
Indium Radioisotopes
Lymphoma/diagnostic imaging
Magnetic Resonance Imaging
Myelolipoma/diagnostic imaging
Octreotide
Positron-Emission Tomography
Radionuclide Imaging
Radiopharmaceuticals
Tomography, X-Ray Computed
Ultrasonography
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Indium Radioisotopes); 0 (Radiopharmaceuticals); 045A6V3VFX (Indium); 0Z5B2CJX4D (Fluorodeoxyglucose F18); 35MRW7B4AD (3-Iodobenzylguanidine); RWM8CCW8GP (Octreotide)
[Em] Entry month:1709
[Cu] Class update date: 170912
[Lr] Last revision date:170912
[Js] Journal subset:IM
[Da] Date of entry for processing:170222
[St] Status:MEDLINE

  9 / 2138 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28026807
[Au] Autor:Tapbergenov SO; Sovetov BS; Tapbergenov AT
[Ad] Address:Department of Biochemistry and Chemical disciplines, Semey State Medical University, Semey, Kazakhstan.
[Ti] Title:Osobennosti vozdeistviia adenozina, AMP i giperadrenalinemii na immunnyi status, fermenty metabolizma purinovykh nukleotidov i sistemu antioksidantnoi zashchity. [Features of influence adenosine, AMP and hyperadrenalinemiya on the immune status, metabolic enzymes of purine nucleotides and the antioxidant defense system].
[So] Source:Biomed Khim;62(6):645-649, 2016 Nov.
[Is] ISSN:2310-6972
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:Administration of a large dose of adrenaline (4 mg/kg 60 min before analysis) increased blood levels of total leukocytes, lymphocytes, decreased T-cell suppressors, leukocyte migration inhibition reaction (LMIR) and NBT test, but increased the level of conjugated dienes (CD). Administration of AMPand adenosine increased levels of total leukocytes, lymphocytes, T- lymphocytes, T-helpers, decreased the level of malondialdehyde (MDA), LMIR, and T-cell suppressors. Sympathetic hyperactivation induced by administration of a large dose of adrenaline (4 mg/kg 60 min before analysis) was accompanied by an increase in heart and liver activities of glutathione peroxidase (GPx), catalase, AMP deaminase (AMPD), and adenosine deaminase (AD). Administration of AMP or adenosine caused a decrease in activities of glutathione reductase (GR), GPx, catalase, a decrease in the MDA level and an increase in activities of AMPD and AD in the heart. In the liver AMP and adenosine also caused a decrease in activities of glutathione reductase (GR), GPx, a decrease in the MDA level and an increase in activities of AMPD and AD. The data obtained suggest that administration of adrenaline, AMP, and adenosine influences activity of enzymes involved in purine nucleotide metabolism. However, in contrast to adrenaline, administration of AMP or adenosine does not provoke stress reaction.
[Mh] MeSH terms primary: AMP Deaminase/blood
Adenosine Deaminase/blood
Adenosine Monophosphate/pharmacology
Adenosine/pharmacology
Adrenocortical Hyperfunction
Oxidoreductases/blood
[Mh] MeSH terms secundary: Adrenocortical Hyperfunction/blood
Adrenocortical Hyperfunction/immunology
Animals
Antioxidants/metabolism
Rats
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antioxidants); 415SHH325A (Adenosine Monophosphate); EC 1.- (Oxidoreductases); EC 3.5.4.4 (Adenosine Deaminase); EC 3.5.4.6 (AMP Deaminase); K72T3FS567 (Adenosine)
[Em] Entry month:1703
[Cu] Class update date: 170321
[Lr] Last revision date:170321
[Js] Journal subset:IM
[Da] Date of entry for processing:161228
[St] Status:MEDLINE
[do] DOI:10.18097/PBMC20166206645

  10 / 2138 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 27901462
[Au] Autor:Le Roux AB; Hickey JM; Noel PG
[Ti] Title:What Is Your Diagnosis?
[So] Source:J Am Vet Med Assoc;249(12):1353-1355, 2016 Dec 15.
[Is] ISSN:1943-569X
[Cp] Country of publication:United States
[La] Language:eng
[Mh] MeSH terms primary: Adrenal Insufficiency/veterinary
Dihydrotestosterone/analogs & derivatives
Dog Diseases/diagnosis
Enzyme Inhibitors/adverse effects
Glucocorticoids/therapeutic use
[Mh] MeSH terms secundary: Adrenal Insufficiency/chemically induced
Adrenal Insufficiency/diagnosis
Adrenal Insufficiency/drug therapy
Adrenocortical Hyperfunction/drug therapy
Adrenocortical Hyperfunction/veterinary
Animals
Dihydrotestosterone/adverse effects
Dihydrotestosterone/therapeutic use
Dog Diseases/drug therapy
Dog Diseases/pathology
Dogs
Enzyme Inhibitors/therapeutic use
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Enzyme Inhibitors); 0 (Glucocorticoids); 08J2K08A3Y (Dihydrotestosterone); L0FPV48Q5R (trilostane)
[Em] Entry month:1707
[Cu] Class update date: 170817
[Lr] Last revision date:170817
[Js] Journal subset:IM
[Da] Date of entry for processing:161201
[St] Status:MEDLINE


page 1 of 214 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information